The alternative text for this image may have been generated using AI. Figure 3: Control of cytokine receptor signaling by CD45. The alternative text for this image may have been generated using AI.
Genomic and immunological characterization between primary and recurrent breast cancer. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text ...
Lurbinectedin in patients with pretreated BRCA1/2-associated metastatic breast cancer: Results from a phase II basket study. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...
--Preclinical data for Cimeio’s CD45 universal heme ADC and shielded HSCs demonstrate effective depletion of an aggressive AML cell line in vivo-- --First data for Cimeio’s CD33 shielded HSCs show ...
A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer. Scientists in the Perelman School ...
-- Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- “Millions of patients worldwide live ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more ...
Know your enemy, know yourself. It’s a centuries-old strategy. But even in the present-day war against cancer, achieving it remains elusive. In many cases, cancer cells blend in with healthy ones.
Dana-Farber Cancer Institute authors: Ali Salehi Farid, PharmD, Jennifer E. Rowley, Harris H. Allen, Isabella G. Kruger, Soheil Tavakolpour, Kyle Neeley, Min Cong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results